Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

Phase 2TerminatedNCT00380783

Allergan2 enrolled

Overview

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Cystitis, Interstitial

Interventions

AGN 203818DRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of painful bladder syndrome/interstitial cystitis * Moderate or severe bladder pain Exclusion Criteria: * Any other uncontrolled disease * Pregnant or nursing females

Locations (1)

Unnamed facility

Oklahoma City, Oklahoma, United States

Outcomes

Primary Outcomes

Reduction in daily pain scores

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.